Trial
NCT06029595
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chiesi Farmaceutici S.p.A.
Collaborators
—
Condition
Uncontrolled Asthma
Intervention
Experimental: CHF6001 3200 μg
Why stopped
Strategic decision by Sponsor; not due to safety reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-18